Viking Therapeutics Clinical Trial Data
Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, demonstrating that less frequent dosing (monthly and every other week) effectively maintained weight loss. Subjects receiving weekly 17.5 mg doses achieved 22% placebo-adjusted weight loss at Week 33, and the drug showed excellent tolerability with GI adverse event rates similar to placebo during the maintenance phase.
- Earnings call
- Sep 29, 2026, 8:00 AM ET
“The results of our innovative maintenance dosing study continue to demonstrate the significance of VK2735’s unique and differentiated half-life and PK profile, which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity.”
Brian Lian, Ph.D., chief executive officer of Viking
“We believe this dose-ranging study clearly demonstrated the potential viability of novel, extended dosing approaches for maintenance following induction with an incretin-based therapy.”
Brian Lian, Ph.D., chief executive officer of Viking